The First Affiliated Hospital of Wenzhou Medical University

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.
  • Details of the presentations are as follows:
    Fruquintinib plus Sintilimab in patients with either treatment naïve or previously treated advanced gastric or gastroesophageal junction adenocarcinoma: results from a multicenter, single-arm phase Ib/II study
    Xiaoli Wei, Harbin Medical University Cancer Hospital, Harbin, China
    First report of the safety/tolerability and preliminary antitumor activity of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer: an open-label, randomized phase Ib/II study
    Wenhua Li, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
    Fuxiang Zhou, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
    Lu Wang, Liver surgery department, Fudan University Shanghai Cancer Center, Shanghai, China
    Pei Ma, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology

Retrieved on: 
Tuesday, February 7, 2023

American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.

Key Points: 
  • American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
  • The journal concluded that monotherapy of orelabrutinib demonstrated compelling efficacy and a well-tolerated safety profile, with a significant number of patients achieving CR in R/R CLL/SLL.
  • The American Journal of Hematology is an academic journal focusing on hematology, which was founded in 1976 and published monthly by WILEY publisher.
  • Note: In addition to background information, the content of this press release is derived from this published article.

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Retrieved on: 
Monday, November 28, 2022

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

From Years to Just One Month: Huawei Cloud's Pangu Drug Molecule Model Accelerates New Drug Discovery

Retrieved on: 
Monday, September 19, 2022

During his speech, Mr. Ken Hu spoke about how the First Affiliated Hospital of the Medical School at Xi'an Jiaotong University used AI to expedite pharmaceutical R&D and new drug discovery.

Key Points: 
  • During his speech, Mr. Ken Hu spoke about how the First Affiliated Hospital of the Medical School at Xi'an Jiaotong University used AI to expedite pharmaceutical R&D and new drug discovery.
  • A major challenge in new drug discovery lies in the screening of hundreds of millions of existing drug molecules.
  • Traditionally, drug screening was performed by experts in labs, which was costly, slow, and had a high failure rate.
  • The Huawei Cloud Pangu Drug Molecule Model has been trained using the data of 1.7 billion drug-life molecules, and can predict the physicochemical properties of drug compounds and score them based on their druglikeness.

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

Retrieved on: 
Wednesday, August 3, 2022

Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
  • In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein.
  • A third trial ( ARYA-3 ) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS T cells (ECT204).

Bionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM

Retrieved on: 
Thursday, May 12, 2022

Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment.

Key Points: 
  • Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment.
  • We believe this paper highlights the growing validation of OGM in different applications for clinical research in cytogenetics.
  • The work by Dr. Kong and his team at Zhengzhou University further extends this validation and highlights the utility of OGM.
  • The Companys mission is to transform the way the world seesthe genome through OGM solutions, diagnostic services and software.

Philips delivers Q4 sales of EUR 4.9 billion and income from continuing operations of EUR 139 million; Adjusted EBITA margin amounts to 13.1%, operating cash flow is EUR 720 million; good demand drives mid-single-digit order intake growth

Retrieved on: 
Monday, January 24, 2022

This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.

Key Points: 
  • This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.
  • Based on good customer demand and our growing order book, we expect to resume our growth and margin expansion trajectory in the course of 2022.
  • For the Group, we target 3-5% comparable sales growth and a 40-90 basis-points improvement in Adjusted EBITA margin.
  • For the full year, the Diagnosis & Treatment businesses recorded 8% comparable sales growth and an Adjusted EBITA margin of 12.4%.

Successful Completion of First Patient Implantation of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in China Announced by Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI

Retrieved on: 
Thursday, January 20, 2022

CATANIA, Italy, Jan. 20, 2022 /PRNewswire/ --SIFI, a leading international ophthalmic company headquartered in Italy, is pleased to divulge the successful completion of the first patient implantation of MINI WELL and MINI WELL TORIC IOLs in China, announced via Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI.

Key Points: 
  • CATANIA, Italy, Jan. 20, 2022 /PRNewswire/ --SIFI, a leading international ophthalmic company headquartered in Italy, is pleased to divulge the successful completion of the first patient implantation of MINI WELL and MINI WELL TORIC IOLs in China, announced via Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI.
  • Developed by SIFI, MINI WELL and MINI WELL TORIC Extended Depth-of-Focus (EDOF) IOLs are innovative IOL implants, offering a great alternative to refraction, diffraction and segment-types mono/bi/tri-focal IOLs, as well as to diffraction-type EDOF IOLs.
  • Mini WELL and Mini WELL Toric are aspheric, single-piece EDOF IOLs specific for the surgical technique of mini-incision and designed for correcting astigmatism and presbyopia.
  • Established in 2021, AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI S.p.A. ("SIFI"), a leading international ophthalmology company headquartered in Italy, to develop, manufacture and commercialize premium intraocular lenses ("IOLs") in the Greater China market.